By ONN Staff


Nurse Takeaways: 2022 ASCO Genitourinary Cancers Symposium at a Glance

April 21, 2022

PARP inhibitors emerge as frontline treatment in metastatic castration-resistant prostate cancer, immunotherapy combinations improve quality of life in advanced renal cell carcinoma, and antibody drug conjugates show promise in cisplatin-ineligible urothelial cancer.

2022 ASCO Gastrointestinal Cancers Symposium Highlights

April 20, 2022

Ivosidenib maintains quality of life in cholangiocarcinoma, immunotherapy outperforms chemotherapy in select gastric/gastroesophageal junction adenocarcinoma, and nivolumab induces high response rates are observed among patients with BRAF V600E–mutant metastatic colorectal cancer.

Voices Behind the Mask: Oncology Nurses Speak Out About Their COVID-19 Experiences

January 10, 2022

Seasoned oncology nurses share how the COVID-19 pandemic has affected the standard of care at their institution, the consequences of the staffing shortage, and how they believe the oncology community can work together to create a better working environment.